Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$58.23
Market cap
$118.1B
P/E Ratio
N/A
Dividend/share
$2.4
EPS
-$3.59
Enterprise value
$159.96B
Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease,
Highlights
The quick ratio has increased by 9% YoY and by 8% QoQ
The company's revenue rose by 6% YoY
BMY's debt is up by 32% year-on-year but it is down by 5% since the previous quarter
Bristol Myers Squibb's EPS has shrunk by 190% YoY and by 10% QoQ
The net income has dropped by 188% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of BMY
Market
Valuations
Earnings
Shares outstanding
2.03B
Market cap
$118.1B
Enterprise value
$159.96B
Price to book (P/B)
6.89
Price to sales (P/S)
2.49
EV/EBIT
N/A
EV/EBITDA
48.58
EV/Sales
3.37
Revenue
$47.44B
EBIT
-$6.89B
EBITDA
$3.29B
Free cash flow
$13.8B
Per share
Balance sheet
Liquidity
EPS
-$3.59
Free cash flow per share
$6.81
Book value per share
$8.46
Revenue per share
$23.4
TBVPS
$22.17
Total assets
$93.67B
Total liabilities
$76.47B
Debt
$49.75B
Equity
$17.14B
Working capital
$5.44B
Debt to equity
2.9
Current ratio
1.24
Quick ratio
0.84
Net debt/EBITDA
12.71
Margins
Efficiency
Dividend
EBITDA margin
6.9%
Gross margin
74.9%
Net margin
-15.3%
Operating margin
-14.5%
Return on assets
-7.6%
Return on equity
-36.3%
Return on invested capital
-11.1%
Return on capital employed
-9.7%
Return on sales
-14.5%
Dividend yield
4.12%
DPS
$2.4
Payout ratio
N/A
BMY stock price
How has the Bristol Myers Squibb stock price performed over time
Intraday
0.6%
1 week
-0.46%
1 month
11.72%
1 year
20.11%
YTD
13.49%
QTD
12.54%
Financial performance
How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$47.44B
Gross profit
$35.53B
Operating income
-$6.88B
Net income
-$7.26B
Gross margin
74.9%
Net margin
-15.3%
The net income has dropped by 188% year-on-year and by 11% since the previous quarter
BMY's net margin has dropped by 183% year-on-year and by 9% since the previous quarter
The operating income has dropped by 180% year-on-year and by 7% since the previous quarter
The operating margin has dropped by 176% year-on-year and by 5% since the previous quarter
Growth
What is Bristol Myers Squibb's growth rate over time
Valuation
What is Bristol Myers Squibb stock price valuation
P/E
N/A
P/B
6.89
P/S
2.49
EV/EBIT
N/A
EV/EBITDA
48.58
EV/Sales
3.37
Bristol Myers Squibb's EPS has shrunk by 190% YoY and by 10% QoQ
BMY's P/B is 68% above its 5-year quarterly average of 4.1 and 30% above its last 4 quarters average of 5.3
Bristol Myers Squibb's equity has decreased by 41% YoY
The price to sales (P/S) is 20% less than the 5-year quarterly average of 3.1 but 13% more than the last 4 quarters average of 2.2
The company's revenue rose by 6% YoY
Efficiency
How efficient is Bristol Myers Squibb business performance
Bristol Myers Squibb's ROA has plunged by 186% YoY and by 10% from the previous quarter
Bristol Myers Squibb's return on sales has shrunk by 176% YoY and by 5% QoQ
BMY's return on invested capital has dropped by 163% year-on-year
The ROE has contracted by 27% from the previous quarter
Dividends
What is BMY's dividend history
DPS
$2.4
Dividend yield
4.12%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Bristol Myers Squibb financials performed over time
BMY's total assets is 22% greater than its total liabilities
The total liabilities has increased by 23% year-on-year
The quick ratio has increased by 9% YoY and by 8% QoQ
BMY's debt is 190% greater than its equity
The company's debt to equity has surged by 123% YoY but it fell by 6% QoQ
Bristol Myers Squibb's equity has decreased by 41% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.